國家衛生研究院 NHRI:Item 3990099045/4699

NHRI > National Institute of Infectious Diseases and Vaccinology > Lan-Lan Liang(1998-2006) > Conference Papers/Meeting Abstract > Item 3990099045/4699

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/4699

Title:	Treating primary dysmenorrhea with a Chinese herb formula, four-agents-decoction
Other Titles:	O-232: Treating primary dysmenorrhea with a Chinese herb formula, four-agents-decoction
Authors:	Liu, J;Liang, L;Lin, K;Liu, Y;Tsai, T;Wang, L
Contributors:	Division of Clinical Research
Abstract:	OBJECTIVE: Four-Agents-Decoction (Si Wu Tang) is a traditional Chi-nese herbal formula widely used for relieving menstrual discomforts formany years, especially in Chinese and Asian populations. We assessed itseffectiveness in treating primary dysmenorrhea by a rigorous clinical trial.DESIGN: a Randomized Placebo-controlled Clinical Trial.MATERIALS AND METHODS: Randomized, double-blind, placebo-controlled clinical trial was conducted between 2001 and 2004 enrolling 78primary dysmenorrheic women after screening 326 women from colleges inthe Taipei metropolitan area of Taiwan. Women had organic lesions wereexcluded, determined by non-invasive pelvic ultrasonography and normalserum CA-125 level. Participants were followed with two to four cycles foran initial washout interval, one to two baseline cycles, three to four treatmentcycles and three follow-up cycles. Menstrual pain intensity wasmeasured by visual analog scale of 0-10 cm on on-line diary.RESULTS: The menstrual pain intensity did not differ by capsulatedFour-Agents-Decoction (FAD) and placebo after 3-cycle treatment. In orderto meet our schedule for group post-treatment examination, 42 women withshorter menstrual cycle had 4 cycles of treatment. To our surprise, theoverall pain (averaged daily pain intensity) was lower in the 20 women withFAD (2.52 2.12) than in the 22 women with placebo (3.90 2.44; p .064).Furthermore, regardless of treatment length, the pain difference persisted tothe first follow-up cycle of post-treatment phase, when all 38 women withFAD (2.63 1.94) were compared to all 38 women with placebo(3.76 2.47; p .029). This significant difference is also attributed to thewomen with 4 treatment cycles (2.18 1.66 for the 20 women with FAD vs.3.93 2.72 for the 22 women with placebo; p .017). The pain intensity ofthe FAD group increased at the second and third follow-up cycles, but stilllower than that at baseline.CONCLUSION: With our dosage regimen and treatment of four cycles,capsulated FAD improves primary dysmenorrhea. Another trial with longertreatment period and larger sample size is needed to study its curing effectand to set an optimal dose, and the validity of the regimen in differentgeographical areas and races. A trial evaluating the effects of the quality ofFAD with the capsulated FAD manufactured from different batches of theherbs should also be conducted.
Date:	2006-09
Relation:	Fertility and Sterility. 2006 Sep;86(Suppl. 2):S99-S100.
Link to:	http://dx.doi.org/10.1016/j.fertnstert.2006.07.265
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0015-0282&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000241038500232
Appears in Collections:	[Lan-Lan Liang(1998-2006)] Conference Papers/Meeting Abstract

Files in This Item:

File	Description	Size	Format
ISI000241038500232.pdf		92Kb	Adobe PDF	622	View/Open

Loading...